ING Groep NV lifted its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 1,311.9% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 9,856,090 shares of the company’s stock after purchasing an additional 9,157,999 shares during the period. Kenvue comprises approximately 1.0% of ING Groep NV’s holdings, making the stock its 19th biggest holding. ING Groep NV’s holdings in Kenvue were worth $170,018,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Physician Wealth Advisors Inc. raised its stake in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in Kenvue in the fourth quarter valued at approximately $26,000. SBI Securities Co. Ltd. raised its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares in the last quarter. Atlantic Union Bankshares Corp raised its stake in Kenvue by 184.1% in the third quarter. Atlantic Union Bankshares Corp now owns 2,619 shares of the company’s stock valued at $43,000 after purchasing an additional 1,697 shares in the last quarter. Finally, Leonteq Securities AG purchased a new stake in Kenvue in the fourth quarter valued at approximately $45,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Kenvue Stock Up 4.9%
Shares of NYSE KVUE opened at $17.72 on Friday. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The firm’s 50 day simple moving average is $17.37 and its two-hundred day simple moving average is $17.48. The stock has a market capitalization of $34.01 billion, a P/E ratio of 20.84, a PEG ratio of 1.34 and a beta of 0.54.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.
Insider Activity
In other news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.59% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on KVUE. UBS Group lowered their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Barclays lowered their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Citigroup lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Canaccord Genuity Group raised their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings downgraded shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $19.33.
Get Our Latest Report on Kenvue
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Stories
- Five stocks we like better than Kenvue
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
